Dublin, Ireland, 11th April 2007 - AGI Therapeutics plc (“AGI” or the “Company”) (AIM, IEX: AGI), a speciality pharmaceutical company focused on gastrointestinal drug products, today announces that it has concluded a successful pre-IND (Investigational New Drug) meeting with the U.S. Food and Drug Administration (FDA) for arverapamil, (AGI-003), AGI’s lead product for irritable bowel syndrome (IBS).
